

01-13-04



CASE 4-30755B

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV335542795US  
Express Mail Label Number

January 12, 2004  
Date of Deposit

1 AF  
\$1617

#21/E  
(NE)  
7/18/05

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

BULLOCK ET AL.

APPLICATION NO: 10/072,516

FILED: FEBRUARY 6, 2002

FOR: ADDITIONAL THERAPEUTIC USE

Art Unit: 1617

Examiner: Kim, J.

RECEIVED

JAN 22 2004

TECH CENTER 1600/2900

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

AMENDMENT AFTER FINAL REJECTION

Sir:

In response to the Office Action mailed July 11, 2003, applicants in the above-identified patent application respectfully request the following amendment be entered and the claims considered in light thereof. Applicants also herein request a three month extension for this response as allowed under 37 C.F.R. § 1.136(a). The Examiner is authorized to charge Deposit Account No. 19-0134 in the name of Novartis Corporation for the fee required under 37 C.F.R. § 1.17(a).

no  
not  
entire  
7/18/05

IN THE CLAIMS:

Claim 7 has been deleted and claims 8, 9, 11, and 12 have been amended as shown in the attached amendment sheet which follows the REMARKS Section of this response.

REMARKS:

The Applicants have deleted claim 7 and amended claims 8, 9, 11, and 12 to clarify the novelty and unobvious nature of the Applicants' invention.